jumped Wednesday after it announced an agreement with
to co-develop a test for peripheral artery disease.
Ciphergen's shares were gaining 10.1% to 98 cents while Quest's shares were down 1.8% to $52.05.
Under the deal, Quest will assist Ciphergen in the development of the blood-based test. The companies previously agreed to jointly develop a test to detect ovarian tumors.
Peripheral artery disease can lead to clogged blood vessels in the arms and legs which, in severe cases, lead to amputation. Peripheral artery disease affects 8 million to 12 million Americans, according to Ciphergen. Research has shown that nearly 75% of people with the disorder do not experience symptoms.